Want to see POM full AI Analyst Report?
POM Stock Chart & Stats
$0.31
--
Market closed
$0.31
--
Day’s Range― - ―
52-Week Range$1.02 - $115.74
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.20M
Market Cap
$8.42M
Enterprise Value$505.22M
Total Cash (Recent Filing)$2.11B
Total Debt (Recent Filing)$37.66B
Price to Earnings (P/E)―
Beta0.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,774,573
10 Day Avg. Volume781,994
30 Day Avg. Volume2,198,746
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-4.75
Price to Sales (P/S)5.39
P/FCF Ratio-14.43
Enterprise Value/Market Cap59.97
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSteady top-line growth through 2025 (≈17% YoY in 2025) indicates sustained demand for PomDoctor’s online hospital and pharmacy services. Durable revenue expansion supports scale economics and provides a foundation to invest in product development and platform expansion over the next several quarters.
Strategic Shift To AI-driven Predictive HealthcareManagement’s move to an AI+wearables+physician-services ecosystem is a structural repositioning into predictive chronic disease management. That diversified, platform-focused model can create network effects, recurring revenue streams, and data assets that compound over time if execution and adoption scale.
Nasdaq Bid-price Compliance RestoredRegaining compliance removes immediate delisting risk and reduces binary operational disruption. Maintaining Nasdaq listing preserves market access, investor visibility and the company’s ability to raise capital in public markets—important for funding product development and execution of long-term strategy.
Bears Say
Highly Stressed Balance SheetNegative equity and materially rising debt materially weaken financial flexibility and increase solvency risk. Over the medium term this constrains borrowing capacity, raises refinancing and covenant risks, and makes the company more vulnerable to adverse shocks or higher funding costs.
Worsening Cash Burn And Negative Cash GenerationPersistent negative operating and free cash flow, and a sharp 2025 deterioration, imply ongoing financing needs and higher dilution risk. Continued cash burn undermines the company’s ability to sustain R&D and go-to-market investments without recurrent capital raises, hampering long-term execution certainty.
Governance And Internal Control ConcernsAn auditor change combined with disclosed material weaknesses signals elevated governance and reporting risk. Persistent control deficiencies can delay filings, increase audit costs, and weaken investor confidence, affecting long-term access to capital and the credibility of financial disclosures.
PomDoctor Ltd. Unsponsored ADR News
POM FAQ
What was PomDoctor Ltd. Unsponsored ADR’s price range in the past 12 months?
PomDoctor Ltd. Unsponsored ADR lowest stock price was $1.02 and its highest was $115.74 in the past 12 months.
What is PomDoctor Ltd. Unsponsored ADR’s market cap?
PomDoctor Ltd. Unsponsored ADR’s market cap is $8.42M.
When is PomDoctor Ltd. Unsponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PomDoctor Ltd. Unsponsored ADR’s earnings last quarter?
Currently, no data Available
Is PomDoctor Ltd. Unsponsored ADR overvalued?
According to Wall Street analysts PomDoctor Ltd. Unsponsored ADR’s price is currently Overvalued.
Does PomDoctor Ltd. Unsponsored ADR pay dividends?
PomDoctor Ltd. Unsponsored ADR does not currently pay dividends.
What is PomDoctor Ltd. Unsponsored ADR’s EPS estimate?
PomDoctor Ltd. Unsponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PomDoctor Ltd. Unsponsored ADR have?
PomDoctor Ltd. Unsponsored ADR has 6,774,573 shares outstanding.
What happened to PomDoctor Ltd. Unsponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PomDoctor Ltd. Unsponsored ADR?
Currently, no hedge funds are holding shares in POM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PomDoctor Ltd. Unsponsored ADR
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.17% Other Institutional Investors
99.83% Public Companies and
Individual Investors